echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Nature sub-journal: Dual-specific CRISPR/Cas nanosystem controls precise treatment of liver disease

    Nature sub-journal: Dual-specific CRISPR/Cas nanosystem controls precise treatment of liver disease

    • Last Update: 2022-10-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    August 24, 2022 / eMedClub News / -- In recent years, the CRISPR-Cas system has shown great application prospects in the treatment of hereditary and non-hereditary liver diseases




    Construction of the bispecific nanosystem





    References:


    1.


    DOI: 10.





    ——List of recent popular activities——



    ▼August 25, research on the upstream production process of GMP-grade lentiviral vectors



    ▼August 29, Phase 2: Immunometabolism Analysis, Helping Cellular Immunotherapy

    ▼August 30, technical application and safety quality control of virus clearance research

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.